Search

Search Constraints

You searched for: Author/Creator Gilbert, Lucy

Search Results

1. 2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study. (20th October 2022)

2. 2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study. (20th October 2022)

3. 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. (20th October 2022)

4. 2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial. (20th October 2022)

5. 2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1. (20th October 2022)

6. 2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68). (20th October 2022)

7. 2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial. (20th October 2022)

9. 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. (10th December 2020)

10. 385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study. (4th December 2020)